Phase 1 trial to investigate novel multi-specific HB2198 to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20...
Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and...
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis,...
- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim...
ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in...
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M...
Second year proceeds granted following FDA review of annual performance progress report on Phase 3 SELVA single-arm, baseline-controlled trial; up...
RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapiesCLEVELAND, Oct. 13,...
– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn.,...
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use...
This milestone marks half a century of innovation, reliability and access to life-saving medicines worldwideWATFORD, United Kingdom and BERWYN, Pa.,...
Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia•Q1 sales AUD$1.6 million up 52% on...
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in...
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30...
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapiesHONG...
Expanding access to fast, accurate syphilis testing to support Australia’s public health response. iStatis Syphilis Antibody Test iStatis Syphilis Antibody...
AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO...
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer...
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer...
Acquisition aims to strengthen the EY organization's Veeva Centers of Excellence, expanding clinical, regulatory and commercial services capabilities for global pharma and...